| Identification | Back Directory | [Name]
Benzamide, 3-[3-[acetyl[[(1R,2R,3S,4R)-4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxycyclopentyl]methyl]amino]-1-propyn-1-yl]- | [CAS]
2928480-72-0 | [Synonyms]
Benzamide, 3-[3-[acetyl[[(1R,2R,3S,4R)-4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxycyclopentyl]methyl]amino]-1-propyn-1-yl]- | [Molecular Formula]
C24H24ClN5O4 | [MOL File]
2928480-72-0.mol | [Molecular Weight]
481.93 |
| Hazard Information | Back Directory | [Uses]
II399 is a potent, selective NNMT bisubstrate inhibitor containing an unconventional SAM mimic, with a Ki of 5.9 nM. II399 exhibits an explicit pattern of competitive inhibition for NAM. II399 occupies both the substrate and cofactor binding pockets. II399 has the potential for the research of cancers, metabolic, cardiovascular, and neurodegenerative diseases[1][2]. | [References]
[1] Meng Y, et al. Comparative Analysis of Two NNMT Bisubstrate Inhibitors through Chemoproteomic Studies: Uncovering the Role of Unconventional SAM Analogue Moiety for Improved Selectivity. ACS Chem Biol. 2024 Jan 19;19(1):89-100. DOI:10.1021/acschembio.3c00531
[2] ID, et, al. Exploring Unconventional SAM Analogues To Build Cell-Potent Bisubstrate Inhibitors for Nicotinamide N-MethyltransferaseIyamu. Angew Chem Int Ed Engl. 2022 Apr 11;61(16):e202114813. DOI:10.1002/anie.202114813 |
|
|